ATNM Share Price | Actinium Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: Is Actinium Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Actinium Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The MACD is showing a mildly bullish stance on both the weekly and monthly time frames, while the RSI indicates a bullish signal on the monthly but no signal on the weekly. The daily moving averages are also mildly bullish. However, the Bollinger Bands present a mixed picture with a bullish signal on the weekly and a bearish signal on the monthly. The KST is mildly bearish on the weekly and bearish on the monthly, and Dow Theory shows no trend on both time frames.In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.79% and -3.51% compared to 1.05% and 2.33% for the index, respectively. However, it has outperformed the S&P 500 year-to-date with a return of 30.95% versus 12.22%. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and daily moving averages.

Q: Is Actinium Pharmaceuticals, Inc. overvalued or undervalued?

As of 15 May 2023, the valuation grade for Actinium Pharmaceuticals, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, particularly given its P/E ratio is not applicable due to losses, while its Price to Book Value stands at 2.22. Additionally, the EV to EBIT and EV to EBITDA ratios are both at a low 0.16, suggesting that the market is not valuing the company's earnings potential favorably.In comparison to its peers, Actinium Pharmaceuticals has a valuation score of -0.9802, while Fusion Pharmaceuticals, Inc. has a P/E of -17.5788 and Zevra Therapeutics, Inc. has a P/E of -5.0550, both indicating a challenging environment for similar firms. The company's return over the past year has been particularly poor at -79.21%, contrasting sharply with the S&P 500's return of 10.26%, further reinforcing the notion that Actinium may not be a viable investment at its current valuation.

Q: How big is Actinium Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Actinium Pharmaceuticals, Inc. has a market capitalization of 44.61 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -45.51 million.Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 32.76 million, while total assets were reported at 76.90 million.

Q: What does Actinium Pharmaceuticals, Inc. do?

Overview:Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in developing cancer treatments within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:- Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025)- Market-cap: USD 44.61 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -2.52- Return on Equity: -177.13%- Price to Book: 1.74Contact Details:- Address: 275 Madison Ave Fl 7, NEW YORK NY: 10016-1101- Tel: 1 646 6773875- Website: https://www.actiniumpharma.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

15.91 k

Shareholding (Jun 2026)

FII

1.79%

Held by 29 FIIs

DII

98.21%

Held by 10 DIIs

Promoter

0.00%

Is Actinium Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Actinium Pharmaceuticals, Inc. shows a mildly bullish trend, supported by the MACD and daily moving averages, despite mixed signals from Bollinger Bands and underperformance against the S&P 500 in the short term.

View full answer

Is Actinium Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2023, Actinium Pharmaceuticals, Inc. is considered overvalued with significant financial concerns, reflected in its low valuation score of -0.9802, a Price to Book Value of 2.22, and a poor one-year return of -79.21%, making it a potentially unviable investment compared to its peers.

View full answer

How big is Actinium Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Actinium Pharmaceuticals, Inc. has a market capitalization of 44.61 million, with net sales of 0.00 million and a net profit of -45.51 million over the latest four quarters. Shareholder's funds are 32.76 million, and total assets are 76.90 million.

View full answer

What does Actinium Pharmaceuticals, Inc. do?

22-Jun-2025

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. As of March 2025, it has a market cap of $44.61 million and reported a net loss of $16 million.

View full answer

Who are in the management team of Actinium Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Actinium Pharmaceuticals, Inc. includes Mr. Sandesh Seth (Chairman and CEO), Dr. C. David Nicholson (Lead Independent Director), and Independent Directors Dr. Jeffrey Chell, Dr. Ajit Shetty, and Mr. Richard Steinhart. They oversee the company's strategic direction and governance.

View full answer

Compare Actinium Pharmaceuticals, Inc. with Similar Stocks

Atara Biotherapeutics, Inc.Alimera Sciences, Inc.Applied Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of INF%, the company declared Outstanding results in Jun 26

The company has declared positive results for the last 5 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD -22.66 MM
ROCE(HY) Highest at 45.86%
RAW MATERIAL COST(Y) Fallen by -9,877% (YoY)

With ROE of -251.01%, it has a does not qualify valuation with a 2.33 Price to Book Value

High Institutional Holdings at 29.68%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 32 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-3.83

Return on Equity

-251.01%

Price to Book

2.33

Revenue and Profits:

Net Sales:

35 Million

(Quarterly Results - Jun 2026)

Net Profit:

28 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

15.69%

6 Months

3.51%

1 Year

-27.16%

2 Years

-35.87%

3 Years

-81.27%

4 Years

-83.84%

5 Years

-86.79%

Actinium Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

1.74%

EBIT Growth (5y)

-28.53%

EBIT to Interest (avg)

-37.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.52

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

29.59%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.33

EV to EBIT

0.55

EV to EBITDA

0.57

EV to Capital Employed

0.53

EV to Sales

-20.65

PEG Ratio

Dividend Yield

ROCE (Latest)

95.75%

ROE (Latest)

-251.01%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 22 Schemes (8.64%)

Foreign Institutions

Held by 29 Foreign Institutions (1.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Mar 2026",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 607.27% vs 6.78% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "28.00",
          "val2": "-5.70",
          "chgp": "591.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "27.90",
          "val2": "-5.50",
          "chgp": "607.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "787.60%",
          "val2": "0.00%",
          "chgp": "78.76%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 11.26% vs 21.72% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-35.40",
          "val2": "-41.30",
          "chgp": "14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.90",
          "val2": "-38.20",
          "chgp": "11.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-402,744.40%",
          "val2": "0.00%",
          "chgp": "-40,274.44%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

35.00

0.00

Operating Profit (PBDIT) excl Other Income

28.00

-5.70

591.23%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

27.90

-5.50

607.27%

Operating Profit Margin (Excl OI)

787.60%

0.00%

78.76%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 607.27% vs 6.78% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-35.40

-41.30

14.29%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-33.90

-38.20

11.26%

Operating Profit Margin (Excl OI)

-402,744.40%

0.00%

-40,274.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 11.26% vs 21.72% in Dec 2024

All Annual Results

Company CV

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Company Coordinates

Company Details

275 Madison Ave Fl 7 , NEW YORK NY : 10016-1101

Tel: 1 646 6773875

https://www.actiniumpharma.com/

Registrar Details

Footer loading